CDT Equity Inc. CDT

CDT Equity Inc. approves a 1-for-25 reverse stock split to comply with the Nasdaq bid-price rule. The reverse split becomes effective Sept 28, 2026 at 5:00 pm ET, with trading on a split-adjusted basis beginning Sept 29 under the ticker CDT on Nasdaq. Every 25 pre-split shares become 1 post-split share; par value remains $0.0001. Proportional adjustments apply to equity awards, convertible securities, and warrants; the number of shares authorized and reserved is adjusted. New CUSIP is 20678X700; post-split outstanding shares estimated at about 1,013,515. No fractional shares will be issued; cash in lieu will be paid. Continental Stock Transfer & Trust Co. will act as exchange agent. Registered holders in book-entry form need not act; street-name holders will have positions auto-adjusted. Forward-looking statements and board authorization for future splits are noted. Reverse stock split reduces count to about 1,013,515 and may affect Nasdaq listing compliance and market sentiment, yielding a moderate impact.

CDT Equity Inc. partners with QIMA Life Sciences to evaluate novel Tapinarof combinations in psoriasis and vitiligo. Partnership advances Tapinarof combination evaluations potentially boosting CDT pipeline progress in key dermatology indications.

CDT Equity Inc. highlights Sarborg’s use of Signature Intelligence and quantum computing models for mental health applications. Sarborg quantum models for mental health signal moderate innovation potential that may influence CDT positioning without guaranteed major trajectory shifts.

CDT Equity Inc. appoints co-founder James Bligh as Chief Executive Officer to lead next phase of growth. Co-founder appointment as CEO supports strategic continuity and growth execution.

CDT Equity Inc. validates enhanced solid-form properties within its IP portfolio. IP portfolio validation strengthens competitive positioning with moderate effects on long-term performance.

CDT Equity Inc. announces investment in Pep'd to expand into the fast-growing US peptide market. Investment in Pep'd enables CDT to enter high-growth peptide sector with major strategic implications.

CDT Equity Inc. increases its stake in Sarborg after Sarborg expands in quantum computing and intellectual property. CDT stake increase in Sarborg quantum expansion creates moderate strategic exposure to new technology.

CDT Equity Inc. highlights Sarborg's patent filing extending Quantum-Enabled PRISM Platform to sugarcane. Patent extends core PRISM platform into new sugarcane applications with potential innovation upside.

CDT Equity Inc. announces strategic investment into Sarborg and expansion into quantum computing. Strategic investment and quantum computing expansion represent major moves likely to alter company trajectory.

CDT Equity Inc. announces debt update alongside securing new loan facility. New loan facility and debt update affect financial structure and liquidity.

CDT Equity Inc. received a Nasdaq deficiency letter for failing to meet continued listing standards. Nasdaq deficiency letter raises delisting risk and sharply weakens investor confidence in CDT Equity Inc.

CDT Equity Inc. secures Canadian patent for AZD5904 in male infertility. Canadian patent for AZD5904 grants IP protection that may support future drug development and modestly affect market sentiment.

CDT Equity Inc. (CDT) advances AstraZeneca PLC (AZN)'s AZD5904 into PCT patent protection stage. Advancing AZD5904 to PCT stage secures international IP protection, boosting CDT's portfolio value and future revenue potential.

CDT Equity Inc. notes Sarborg's filing of a substance of matter patent in the cystic fibrosis market. Sarborg's patent filing targets cystic fibrosis, a key therapeutic area, supporting CDT's innovation efforts with moderate impact on competitive positioning.

CDT Equity Inc. (CDT) advances AZD5904 into global patent phase and initiates partnering discussions. Advancing AZD5904 to global patents and starting partnerships represents a major strategic milestone enhancing IP protection and revenue potential.

CDT Equity Inc. (CDT) expands its multi-pathway value creation strategy across pharmaceuticals, intellectual property, and AI-driven discovery. Strategic expansion into pharma, IP, and AI-driven discovery constitutes major moves poised to alter competitive positioning and investor sentiment.

CDT Equity Inc. expands its Tapinarof intellectual property portfolio with two new patent filings. New patent filings for Tapinarof strengthen CDT's IP protection, enhancing competitive positioning and long-term revenue potential.

CDT Equity Inc. (CDT) identifies rare disease opportunities through Sarborg Signature Analysis, advancing its out-licensing strategy. Identifying rare disease opportunities via proprietary analysis advances out-licensing, enabling potential partnerships and revenue streams that could significantly boost CDT's trajectory.

CDT Equity Inc. (CDT) stockholders approved all proposals at a special meeting, positioning the company for its next phase of growth. Stockholder approval of all proposals enables major strategic moves positioning CDT for growth, significantly impacting future performance.

CDT Equity Inc. notes Sarborg's expansion into rare disease signature intelligence. Sarborg's expansion into rare disease intelligence may enhance CDT's portfolio value and competitive positioning in biotech investments.

CDT Equity Inc. (CDT) positions for transformational growth through strategic initiatives. Strategic positioning for transformational growth signals major moves likely to significantly impact CDT's future trajectory and market performance.

CDT Equity Inc. (CDT) highlights Sarborg's expansion into bacteria and agrochemicals sectors. Sarborg's expansion into bacteria and agrochemicals signals major strategic growth diversifying CDT's portfolio and enhancing future revenue prospects.

CDT Equity Inc. (CDT) acquires strategic stake in Sarborg to transform its AI-driven asset strategy. Strategic acquisition in Sarborg enables transformation of CDT's AI-driven asset strategy, significantly impacting competitive positioning and investor sentiment.

CDT Equity Inc. has announced a reverse stock split aimed at increasing the per-share price of its common stock. The company will implement a 1-for-10 reverse split, meaning that every ten shares will be consolidated into one share. This move is intended to meet the minimum bid price requirement for continued listing on the Nasdaq stock exchange. The reverse split is expected to take effect on a specified date, and shareholders will receive a proportional reduction in the number of shares they hold. The reverse stock split may improve the stock's market perception and compliance with listing requirements, but its overall impact on long-term performance remains uncertain.

CDT Equity Inc. (CDT) has been identified as one of the most active stocks in the market, indicating heightened trading activity and investor interest. This surge in activity may reflect broader market trends or specific developments related to the company. Investors are closely monitoring CDT's performance as it could signal potential opportunities or risks in the near future. Increased trading activity suggests a moderately noticeable influence on market sentiment and potential financial performance.

CDT Equity Inc. has identified a new biological target that supports its AI-driven drug repurposing strategy. This development is expected to enhance the company's research capabilities and potentially lead to new therapeutic applications, validating its innovative approach in the pharmaceutical sector. Identifying a new biological target could significantly impact CDT's strategic direction and market positioning.

Conduit Pharmaceuticals Inc. has entered a joint development agreement with Manoira Corporation to advance its glucokinase activators AZD1656 and AZD5658 in animal health. The collaboration aims to generate valuable translational data for both veterinary and human applications, focusing initially on animal osteoarthritis. This partnership allows Conduit to retain full ownership of intellectual property while enhancing its pipeline and exploring the $15 billion animal health market. Manoira will fund the development activities and receive an upfront payment of $500,000 in shares. The agreement is expected to accelerate Conduit's understanding of its drug candidates and create new revenue opportunities. The joint development agreement significantly expands Conduit's market reach and enhances its product pipeline, likely impacting future performance and investor sentiment.

Conduit Pharmaceuticals Inc. has announced its listing on the Nasdaq Capital Market, marking a significant milestone for the company. This move is expected to enhance its visibility and access to capital, potentially benefiting its growth and development initiatives. The listing is part of Conduit's strategy to expand its market presence and attract investors, which could lead to increased financial opportunities. Listing on the Nasdaq Capital Market is a significant strategic move that can enhance visibility and access to capital, impacting future growth.

Conduit Pharmaceuticals Inc. has regained compliance with Nasdaq's minimum bid price and stockholders' equity requirements, allowing its securities to continue being listed and traded on The Nasdaq Stock Market. A Discretionary Panel Monitor will be imposed for one year to ensure long-term compliance. Conduit focuses on developing Phase 2-ready assets using an AI-driven approach and aims for exits through third-party licensing deals after successful clinical trials. Regaining compliance with Nasdaq requirements positively influences Conduit's market position but does not fundamentally alter its business trajectory.

Conduit Pharmaceuticals Inc. has announced a 1-for-15 reverse stock split, approved by its board and stockholders, effective May 19, 2025. The common stock will trade on a reverse stock split-adjusted basis on Nasdaq starting May 20, 2025. The number of outstanding shares will decrease to approximately 755,900, with no fractional shares issued. Stockholders will receive cash for any fractional shares. The company's transfer agent will manage the exchange process, and proportional adjustments will be made to equity awards and convertible securities. The reverse stock split may influence market perception and stock price but is not expected to fundamentally alter the company's trajectory.